Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

A Validated LC-MS/MS Method for the Determination of Mezlocillin in Plasma: An Adapted Method for Therapeutic Drug Monitoring in Children

Author(s): Bo-Hao Tang, Min Kan, Xin-Mei Yang, Rong-Hua Wang, Hai-Yan Shi, Yi Zheng, Guo-Xiang Hao, Lin-Lin Song* and Wei Zhao*

Volume 17, Issue 7, 2021

Published on: 17 May, 2020

Page: [853 - 860] Pages: 8

DOI: 10.2174/1573412916999200517113525

Price: $65

Abstract

Background: Mezlocillin is off-label used for the treatment of respiratory infections in children. Therapeutic Drug Monitoring (TDM) data are also limited in children. A sensitive Liquid chromatography- tandem mass spectrometry (LC–MS/MS) method adapted to children was developed and validated for the determination of mezlocillin plasma concentration in the present study.

Methods: Mezlocillin, extracted from a volume of 50 μL plasma using acetonitrile, was analyzed on an online LC-MS/MS system with an Agilent 1290 Infinity UHPLC (Agilent Technologies, CA, USA) coupled to an AB SCIEX QTRAP 6500PLUS MS/MS (AB Sciex, Framingham, MA, USA) with ceftiofur as an internal standard. HPLC separation was performed on a C18 column with ultra-pure water and acetonitrile as gradient elution at a flow rate of 0.4 mL/min at 30°C. Analyst TM Version 1.5.2 (Applied Biosystems) was used for data acquisition. The total chromatographic run time was 1.6 min.

Results: LC/MS/MS method used for TDM of mezlocillin in children was developed and validated. This assay has a lower limit of quantification of 0.025 μg/mL for mezlocillin with 50 μL plasma. Good linearity was achieved for mezlocillin over the range from 0.025 to 20 μg /mL. The acceptance criteria were met in all cases. Among 36 patients aged between 0.16-1.63 years old, only one patient had detectable trough concentration higher than 1 μg/mL.

Conclusion: LC-MS/MS method with 50 μL plasma developed in this study was successfully applied to TDM of mezlocillin in children. The high variability of trough concentration highlighted that TDM is important to optimize mezlocillin therapy in children.

Keywords: Mezlocillin, LC-MS/MS, children, therapeutic drug monitoring, plasma, quantification.

« Previous Next »
Graphical Abstract

[1]
Bergan, T. Review of the pharmacokinetics of mezlocillin. J. Antimicrob. Chemother., 1983, 11(Suppl. C), 1-16, 1-16.
[http://dx.doi.org/10.1093/jac/11.suppl_C.1] [PMID: 6352604]
[2]
McCloskey, R.V.; LeFrock, J.L.; Smith, B.R.; Aronoff, G.R. Microbiology, pharmacology, and clinical use of mezlocillin sodium. Pharmacotherapy, 1982, 2(6), 300-312.
[http://dx.doi.org/10.1002/j.1875-9114.1982.tb03204.x] [PMID: 6220263]
[3]
Bergan, T. Pharmacokinetics of mezlocillin in healthy volunteers. Antimicrob. Agents Chemother., 1978, 14(6), 801-806.
[http://dx.doi.org/10.1128/AAC.14.6.801] [PMID: 742869]
[4]
Esmieu, F.; Guibert, J.; Rosenkilde, H.C.; Ho, I.; Le Go, A. Pharmacokinetics of cefotaxime in normal human volunteers. J. Antimicrob. Chemother., 1980, 6(Suppl. A), 83-92.
[5]
Ings, R.M.; Fillastre, J.P.; Godin, M.; Leroy, A.; Humbert, G. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. Rev. Infect. Dis., 1982, 4(Suppl.), S379-S391.
[http://dx.doi.org/10.1093/clinids/4.Supplement_2.S379]
[6]
Verbist, L.; Tjandramaga, T.B.; Verbesselt, R.; de Schepper, P.J. Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author’s transl). Nouv. Presse Med., 1982, 11(5 Pt 2), 347-352.
[PMID: 6460974]
[7]
Konus, M.; Aydemir, S.; Yilmaz, C.; Kivrak, A.; Kizildogan, A.K.; Arpac, P.U. Synthesis and evaluation of antioxidant, antimicrobial and anticancer properties of 2-(prop-2-yn-1-yloxy)benzaldehyde derivatives. Lett. Org. Chem., 2019, 16(5), 415-423.
[http://dx.doi.org/10.2174/1570178616666181116100232]
[8]
Pickering, L.K.; Kramer, W.G.; Armes, D.A.; Frankel, L.S.; Townsend, I.R.; Culbert, S. Clinical pharmacology and efficacy of mezlocillin in paediatric patients with malignancy. J. Antimicrob. Chemother., 1982, 9(Suppl. A), 245-250.
[9]
Gundert-Remy, U.; Hildebrandt, R.; Stiehl, A.; Weber, E. Nonlinear mezlocillin kinetics due to dose-dependent metabolism. Clin. Pharmacol. Ther., 1983, 33(5), 656-662.
[http://dx.doi.org/10.1038/clpt.1983.89] [PMID: 6220858]
[10]
Algso, M.A.S.; Kivrak, A.; Konus, M.; Kurt-Kizildoğan, C.Y.A. Synthesis and biological evaluation of novel benzothiophene derivatives. J. Chem. Sci., 2018, 130(9), 119.
[http://dx.doi.org/10.1007/s12039-018-1523-3]
[11]
Wayne, P.A. Performance standards for antimicrobial susceptibility testing, 26th ed; CLSI, 2016.
[12]
Odio, C.; Threlkeld, N.; Thomas, M.L.; McCraken, G.H., Jr Pharmacokinetic properties of mezlocillin in newborn infants. Antimicrob. Agents Chemother., 1984, 25(5), 556-559.
[http://dx.doi.org/10.1128/AAC.25.5.556] [PMID: 6563875]
[13]
Li, Q.; Shi, H-Y.; Wang, K.; Kan, M.; Zheng, Y.; Hao, G-X.; Yang, X-M.; Yang, Y-L.; Su, L-Q.; Zhao, W. Determination of loratadine and its active metabolite in plasma by LC/MS/MS: An adapted method for children. Curr. Pharm. Anal., 2019, 15, 1-6.
[http://dx.doi.org/10.2174/1573412915666190416121233]
[14]
Wu, Y-E.; Wu, X-F.; Kan, M.; Shi, H-Y.; Liu, M-J.; Dong, Q.; Chen, X-K. Huang, X.; Zheng, Y.; Zhao, W. A sensitive microscale HPLC-UV method for the determination of doxofylline and its metabolites in plasma: an adapted method for therapeutic drug monitoring in children. Curr. Pharm. Anal., 2020, 16, 47-54.
[http://dx.doi.org/10.2174/1573412914666180611103849]
[15]
Gundert-Remy, U.; De Vries, J.X. Determination of the ureidopenicillins azlocillin, mezlocillin and bay K 4999 in plasma by high performance liquid chromatography. Br. J. Clin. Pharmacol., 1979, 8(6), 589-592.
[http://dx.doi.org/10.1111/j.1365-2125.1979.tb01049.x] [PMID: 533580]
[16]
Fiore, D.; Auger, F.A.; Drusano, G.L.; Dandu, V.R.; Lesko, L.J. Improved micromethod for mezlocillin quantitation in serum and urine by high-pressure liquid chromatography. Antimicrob. Agents Chemother., 1984, 26(5), 775-777.
[http://dx.doi.org/10.1128/AAC.26.5.775] [PMID: 6517560]
[17]
Jungbluth, G.L.; Janicke, D.M.; Jusko, W.J. Reversed-phase high-performance liquid chromatographic assay for the determination of mezlocillin in human and rat biological samples. J. Chromatogr. A, 1989, 494, 376-380.
[http://dx.doi.org/10.1016/S0378-4347(00)82691-2] [PMID: 2584336]
[18]
Zora, M.; Kivrak, A. Synthesis of pyrazoles via CuI-mediated electrophilic cyclizations of α,β-alkynic hydrazones. J. Org. Chem., 2011, 76(22), 9379-9390.
[http://dx.doi.org/10.1021/jo201685p] [PMID: 21992574]
[19]
Agency, E.M. Guideline on bioanalytical method validation., https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf
[20]
Administration, U.S.F.D. Guidance for Industry Bioanalytical Method Validation., https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf
[21]
Leroux, S.; Turner, M.A.; Guellec, C.B.; Hill, H.; van den Anker, J.N.; Kearns, G.L.; Jacqz-Aigrain, E.; Zhao, W. Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design. Clin. Pharmacokinet., 2015, 54(12), 1273-1285.
[http://dx.doi.org/10.1007/s40262-015-0291-1] [PMID: 26063050]

Rights & Permissions Print Cite
Article Metrics
34
1
© 2024 Bentham Science Publishers | Privacy Policy